Company news
Osteopore Ltd. (ASX:OSX) news
Osteopore Ltd. news releases on 6ix. Latest, Apr 15, 2024: Response to ASX Query Letter
Press releases — page 2
Response to ASX Query Letter
April 15, 2024
Osteopore extends Bridging Loan maturity date
April 10, 2024
Replacement Prospectus for Renounceable Rights Issue
April 4, 2024
Update to Replacement Prospectus for Entitlement Offer
April 3, 2024
Osteopore secures Singapore and Vietnam market approvals
March 26, 2024
Prospectus for Renounceable Rights Issue
March 12, 2024
OSX Entitlement Offer to support growth
March 12, 2024
Activities Update Qtr Ending December 2023 and Appendix 4C
January 30, 2024
Notice of General Meeting
January 23, 2024
Osteopore signs Bridging Loan agreement
December 28, 2023
Activities Update Qtr Ending September 2023 and Appendix 4C
October 30, 2023
MOU with Temasek-linked Innoventures - Orthopaedics in China
September 11, 2023
Activities Update Qtr Ending June 2023 and Appendix 4C
July 30, 2023
OSX receives A$10m commitment for commercialisation in China
July 24, 2023
Osteopore strengthens Board & Management by key appointments
July 17, 2023
Strategic Partnership for Clinical R&D in China worth $4M
June 7, 2023
Largest South African Medical Insurer provides cover for OSX
May 15, 2023
Activities Update Qtr Ending March 2023 and Appendix 4C
April 27, 2023
OSX Successfully transitions to EU Medical Device Regulation
April 26, 2023
Reinstatement of Security Class to Quotation
April 25, 2023
Security Class Suspension from Quotation
April 24, 2023
Non-Renounceable Entitlement Offer - Results
April 24, 2023
OSX Strengthens Presence in the Eastern Region of the USA
April 10, 2023
OSX Completes Acquisition to Accelerate Revenue Growth
March 30, 2023
Non-Renounceable Entitlement Offer Prospectus
March 12, 2023
Non-Renounceable Entitlement Offer
March 12, 2023
Activities Update Qtr Ending December 2022 and Appendix 4C
January 30, 2023
Integration of Acquired Business for Higher Sales & Margin
January 22, 2023
Firm Commitments and Non-Binding Proposed Acquisition
December 21, 2022
Suspension from Official Quotation
December 20, 2022
Increased presence and commercial opportunities across SEA
December 7, 2022
Activities Update Qtr Ending September 2022 and Appendix 4C
October 30, 2022
Osteopore Moves Closer to China Market Entry
August 22, 2022
Activities Update Qtr Ending June 2022 and Appendix 4C
July 25, 2022
OSX Enter Oral & Maxillofacial Market in Australia & NZ
May 10, 2022
Activities Update Qtr Ending March 2022 and Appendix 4C
April 28, 2022
SHG: & CSIRO AI Tool to Optimise Cranial Implant Procedures
March 13, 2022
Activities Update Qtr Ending December 2021 and Appendix 4C
January 27, 2022
Osteopore secures A$19m clinical-industrial partnership
December 13, 2021
Activities Update Qtr Ending September 2021 and Appendix 4C
October 29, 2021
SHG: CSIRO Collaboration for AI-based Tool
October 18, 2021
Activities Update Qtr Ending June 2021 and Appendix 4C
July 30, 2021
Activities Update Qtr Ending March 2021 and Appendix 4C
April 30, 2021
Agreement with Terumo Blood and Cell Technologies
January 31, 2021
Activities Update Qtr Ending December 2020 and Appendix 4C
January 29, 2021
OSX Signs Australian & New Zealand Distribution Agreement
October 30, 2020
Activities Update Qtr Ending September 2020 and Appendix 4C
October 29, 2020
Investor Presentation
August 21, 2020
Osteopore Receives Binding Commitments for $8.5m Placement
August 20, 2020
Activities Update Quarter Ending June 2020 and Appendix 4C
July 31, 2020